Bandingkan Harga & Kinerja Phapros Tbk. (PEHA) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Phapros Tbk. dan Organon Pharma Indonesia Tbk.: Phapros Tbk. diperdagangkan di Rp298 (kapitalisasi pasar 250,32 M, volume 24 jam 116,6 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Phapros Tbk. jauh lebih besar — sekitar 2,4× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| PEHA | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 250,32 M | 104,4 M |
Volume | 116,6 rb | — |
Lot | 1,17 rb | — |
Perputaran | 34,22 jt | — |
Harga Rata-rata | 293,45 | — |
Nilai Transaksi | 34,22 jt | — |
Harga Ekuilibrium Indikatif | 300 | — |
Volume Ekuilibrium Indikatif | 7 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Phapros Tbk.
PT Phapros Tbk was established under the name of N.V. Pharmaceutical Processing Industries, in short N.V. Phapros, based on Notarial Deed No 54 of Tan A Sioe dated 21 June 1954, which later became PT Pharmaceutical Processing Industries, in short PT Phapros based on Notarial Deed No.43 of E. Pondaag, replacing R.M. Soerojo, dated 5 September 1995, which finally became PT Phapros based on Notarial Deed No. 48 of Prof. Dr. Liliana Tedjosaputro, S.H., M.H., MM., dated 12 April 2006. The Company’s immediate and ultimate parent entity is PT Rajawali Nusantara Indonesia, incorporatedand domiciled in Indonesia.
Selengkapnya di halaman PEHA →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
